ArticleJournal of ovarian research2026
The oncology and fertility outcomes in patients with ovarian steroid cell tumors: a single center experience.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveOvarian steroid cell tumor (SCT) is a rare ovarian neoplasm with uncertain malignant potential. This study aimed to evaluate the oncologic and reproductive outcomes of patients with ovarian SCTs.
methodsWe retrospectively reviewed patients with ovarian SCTs who underwent surgery at Peking Union Medical College Hospital between January 2008 and August 2025. Patients were classified into fertility-sparing surgery (FSS) and non-FSS groups according to surgical approach. Clinical features, oncologic outcomes, hormonal recovery, and reproductive outcomes were analyzed.
resultsThirty patients were included, with 19 in the FSS group and 11 in the non-FSS group. The median age of patients was 27 (range: 4-42) in the FSS group and 55 (range: 25-80) in the non-FSS group (P < 0.001). In the FSS group, 63.2% (12/19) of patients had FIGO stage IA disease, 26.3% (5/19) had stage IC1 disease, and 10.5% (2/19) had stage II disease, whereas all patients in the non-FSS group had FIGO stage IA disease (P = 0.029). Elevated serum testosterone levels with virilizing manifestations were observed in all FSS patients and in 45.5% of non-FSS patients. No recurrence was observed among patients with FIGO stage IA disease in either group. Recurrences occurred in a patient with stage IC who underwent ovarian cystectomy and in two patients with stage II in the FSS group, one of whom died of disease. At the last follow-up, only one patient clearly reported an active desire for childbearing and subsequently achieved a spontaneous twin pregnancy with live birth. Median follow-up was 61 months (range: 6-184) in the FSS group and 67 months (range: 4-160) in the non-FSS group.
conclusionOvarian SCTs confined to FIGO stage IA were associated with favorable oncologic outcomes in our cohort, whereas recurrence occurred in patients with stage IC or II disease. For patients with stage IA disease desiring fertility preservation, unilateral salpingo-oophorectomy (USO) may be considered. Fertility preservation in stage IC or II disease should be individualized with caution. Long-term follow-up and multi-institutional studies are needed to better define both oncologic and reproductive outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.